Alzheimer’s Drug Likely to Be FDA Approved Despite Potential Risks


Drug is reasonably likely to result in a clinical benefit and granted approval. Despite potential risks. NBC's Brian Clark with details The FDA s decision to grant accelerated approval to Biogen's new Alzheimer's drug is a historic first in the fight against the disease. It's not a cure. It's not a panacea, but it is a first line treatment that that does look at the underlying cause of the disease. Dr. Joanne Pike, the chief strategist of the Alzheimer's association, points out Alzheimer's remains a fatal disease. We have to have a first line treatment before we can get to a second line or a third line, Dr Pike says. This requires the health care system do prioritize Early detection. Brian Clark ABC News The Department of Justice

Coming up next